Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma

Wang,Jiajun; Liu,Li; Long,Qilai; Bai,Qi; Xia,Yu; Xi,Wei; Xu,Jiejie; Guo,Jianming

doi:10.3892/ol.2017.6362

Decreased expression of JMJD3 predicts poor prognosis of patients with clear cell renal cell carcinoma

Authors:
- Jiajun Wang
- Li Liu
- Qilai Long
- Qi Bai
- Yu Xia
- Wei Xi
- Jiejie Xu
- Jianming Guo
View Affiliations

Affiliations: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, P.R. China
Published online on: June 9, 2017 https://doi.org/10.3892/ol.2017.6362
Pages: 1550-1560
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated abnormal H3K27 methylation status during clear cell renal cell carcinoma (ccRCC) carcinogenesis, and have suggested that the histone H3K27 demethylases, jumonji domain‑containing protein 3 (JMJD3) and ubiquitously‑transcribed TPR gene on the X chromosome, are important regulatory factors that alter H3K27 methylation status. The present study aimed to explore the prognostic value of JMJD3 in patients with ccRCC. A total of 331 ccRCC samples were stained for JMJD3 by immunohistochemistry. Stage, Size, Grade and Necrosis (SSIGN) and University of California Los Angeles Integrated Staging System (UISS) scores were applied to stratify risks. Survival analyses were performed through the Kaplan‑Meier estimator method and Cox proportional hazard model. The results revealed that JMJD3 expression in ccRCC was significantly increased compared with that in the peritumoral tissue (P<0.001) and negatively associated with a number of other clinicopathological characteristics. Kaplan‑Meier estimator and multivariate analyses revealed that decreased tumoral JMJD3 expression was associated with OS (hazard ratio, 2.141; P=0.003), and DFS prediction (hazard ratio, 1.737; P=0.033). In addition, following stratification of patients into three risk levels using the SSIGN and UISS scores, decreased tumoral JMJD3 expression was associated with shorter OS (P=0.003 for SSIGN and UISS scores) and DFS (P=0.007 for SSIGN and P=0.041 for UISS score) in the intermediate risk groups. The results from the present study suggest that JMJD3 is a novel prognostic marker for patients with ccRCC and is of particular significance in patients with intermediate-risk disease.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
3	Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 6:655–663. 1982. View Article : Google Scholar : PubMed/NCBI
4	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
5	Volpe A and Patard JJ: Prognostic factors in renal cell carcinoma. World J Urol. 28:319–327. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hoffman AM and Cairns P: Epigenetics of kidney cancer and bladder cancer. Epigenomics. 3:19–34. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chi P, Allis CD and Wang GG: Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 10:457–469. 2010. View Article : Google Scholar : PubMed/NCBI
8	Yamaguchi H and Hung MC: Regulation and Role of EZH2 in Cancer. Cancer Res Treat. 46:209–222. 2014. View Article : Google Scholar : PubMed/NCBI
9	Greer EL and Shi Y: Histone methylation: A dynamic mark in health, disease and inheritance. Nat Rev Genet. 13:343–357. 2012. View Article : Google Scholar : PubMed/NCBI
10	Liu L, Xu Z, Zhong L, Wang H, Jiang S, Long Q, Xu J and Guo J: Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. BJU Int. 117:351–362. 2016. View Article : Google Scholar : PubMed/NCBI
11	Svotelis A, Bianco S, Madore J, Huppé G, Nordell-Markovits A, Mes-Masson AM and Gévry N: H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency. EMBO J. 30:3947–3961. 2011. View Article : Google Scholar : PubMed/NCBI
12	Xiang Y, Zhu Z, Han G, Lin H, Xu L and Chen CD: JMJD3 is a histone H3K27 demethylase. Cell Res. 17:850–857. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ene CI, Edwards L, Riddick G, Baysan M, Woolard K, Kotliarova S, Lai C, Belova G, Cam M, Walling J, et al: Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One. 7:e514072012. View Article : Google Scholar : PubMed/NCBI
14	Shen Y, Guo X, Wang Y, Qiu W, Chang Y, Zhang A and Duan X: Expression and significance of histone H3K27 demethylases in renal cell carcinoma. BMC Cancer. 12:4702012. View Article : Google Scholar : PubMed/NCBI
15	Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS and Zincke H: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer. 97:1663–1671. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA and Belldegrun AS: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 19:1649–1657. 2001. View Article : Google Scholar : PubMed/NCBI
17	Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL and Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol. 168:2395–2400. 2002. View Article : Google Scholar : PubMed/NCBI
18	Liu H, Xu J, Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y and Gu J: Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 71:7547–7557. 2011. View Article : Google Scholar : PubMed/NCBI
19	Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 46:5419–5425. 1986.PubMed/NCBI
20	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
21	Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, et al: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 440:1045–1049. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hong S, Cho YW, Yu LR, Yu H, Veenstra TD and Ge K: Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc Natl Acad Sci USA. 104:pp. 18439–18444. 2007; View Article : Google Scholar : PubMed/NCBI
23	Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J and Helin K: The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23:1171–1176. 2009. View Article : Google Scholar : PubMed/NCBI
24	Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
25	Aird KM and Zhang R: Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 356:204–210. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sherr CJ: The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2:731–737. 2001. View Article : Google Scholar : PubMed/NCBI
27	Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenführ M, Maertens G, Banck M, Zhou MM, Walsh MJ, et al: Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23:1177–1182. 2009. View Article : Google Scholar : PubMed/NCBI
28	Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al: A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 488:404–408. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chen S and Shi Y: A new horizon for epigenetic medicine? Cell Res. 23:326–328. 2013. View Article : Google Scholar : PubMed/NCBI